Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma

Table 1 Patient and tumor characteristics

Characteristics	Values
Male/female	20/10
Age, yr (mean ± SD)	71.1 ± 9.7
Surgical resection/endoscopic resection	14/16
Location: Siewert I/II	12/18
Tumor size, mm (mean ± SD)	27.1 ± 19.9
Depth of primary tumor: T1a/T1b/T2/T3/T4	13/13/1/2/1
Macroscopic appearance: 0-I/0-IIa/0-IIb/0-IIc/3	8/8/1/11/3
Histology: tub1/tub2	21/9
Histology tub1/tub2: mucin phenotype G/GI/I/N	7/12/8/3
p53: positive/negative	20/10

G: Gastric phenotype; GI: Gastrointestinal phenotype; I: Intestinal phenotype; N: Null type.

Table 2 Comparison of pT1 tumor and all stage tumor characteristics

	pT1 tumor		All stage tumor
	HER2+	HER2-	HER2+ (27%)	HER2- (73%)
Male/female	3/4	13/6	4/4	16/6
Age, yr (mean ± SD)	70.6 ± 9.9	71.4 ± 10.8	70.3 ± 9.2	71.4 ± 10.0
Location: Siewert I/II	3/4	11/18	3/5	9/13
Tumor size, mm (mean ± SD)	20.6 ± 17.7	23.9 ± 16.6	23.6 ± 18.5	28.3 ± 20.7
Depth of primary tumor: T1a/T1b	3/4	10/9	3/4/0/0/1	10/9/1/2/0
Macroscopic appearance: 0-I/0-IIa/0-IIb/0-IIc	3/3/0/1	4/4/1/10	3/3/0/1/1	4/5/1/10/2
Histology: tub1/tub2	7/1	14/5	7/1	14/8
Mucin phenotype: G/GI/I/N	4/2/1/0	3/9/6/1	4/2/2/0	3/10/6/3
p53: positive/negative	7/0	10/9	8/0	12/10

The human epidermal growth factor receptor 2 (HER2)-positive cases were significantly associated with protruding lesions compared with the HER2-negative cases (P < 0.05), and the p53-positivity rate was more common in the HER2-positive tumors (P < 0.05). G: Gastric phenotype; GI: Gastrointestinal phenotype; I: Intestinal phenotype; N: Null type.